Abstracts Archive - Page 935 of 2607 - ACR Meeting Abstracts

Abstract Number: 1479 • ACR Convergence 2020
Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry
Jasmin Kuemmerle-Deschner¹, Birgit Kortus-Goetze², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Ales Janda⁶, Tilmann Kallinich⁷, Prasad T. Oommen⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Norbert Blank¹², ¹University Hospital Tuebingen, Tuebingen, Germany, ²Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Department of Pediatrics, University Hospital Ulm, Germany, Ulm, Germany, ⁷Charite, Berlin, Germany, ⁸Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany
Background/Purpose: In the treatment of monogenic autoinflammatory diseases (AID), a heterogeneous group of diseases with excessive interleukin (IL)-1β release and severe systemic and organ inflammation,…
Abstract Number: 1480 • ACR Convergence 2020
Abatacept for the Treatment of IgG4-Related Disease
Mark Matza¹, Cory Perugino¹, Liam Harvey², Zachary Wallace³, Hang Liu⁴, Shiv Pillai⁵ and John H. Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital, Cambridge, MA, ⁵Harvard Medical School, Cambridge, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: To assess the efficacy and safety of abatacept (ABA) for the treatment of IgG4-related disease (IgG4-RD). To date, there are no FDA-approved treatments available…
Abstract Number: 1481 • ACR Convergence 2020
A Systematic Review to Quantify the Extent of Pharmaceutical Company Involvement in Rheumatology Consensus-Based Recommendations
Dominique Feterman Jimenez¹, Garret Duron², Ali Duarte-Garcia³, Paul Sufka⁴, Samuel Whittle⁵, Philip Robinson⁶, Larry Prokop³ and Michael Putman⁷, ¹UConn Health Center, Farmington, CT, ²HCA Memorial Health University Medical Center, Savannah, GA, ³Mayo Clinic, Rochester, MN, ⁴Healthpartners, St Paul, ⁵Rheumatology Unit, The Queen Elizabeth Hospital, Springfield, South Australia, Australia, ⁶University of Queensland, Herston, Queensland, Australia, ⁷Northwestern University, Chicago, IL
Background/Purpose: Consensus-based recommendations guide standards of care for clinical practice. Pharmaceutical-industry involvement in producing such recommendations may undermine their objectivity. We performed a systematic review…
Abstract Number: 1482 • ACR Convergence 2020
Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis
John Carrino¹, Timothy McAlindon², Eric Vignon³, Mark Brown⁴, Aimee Burr⁴, Robert Fountaine⁴, Glenn Pixton⁵, Lars Viktrup⁶, Christine West⁷ and Kenneth Verburg⁸, ¹Hospital for Special Surgery, Hackensack, NJ, ²Tufts Medical Center, Boston, MA, ³Université Claude Bernard Lyon 1, Pierre Benite, France, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: Tanezumab, a monoclonal antibody that inhibits nerve growth factor, has been shown effective in the management of osteoarthritis (OA) pain.1,2 Due to the potential…
Abstract Number: 1483 • ACR Convergence 2020
A Randomised Controlled Trial Evaluating the Efficacy of Internet-based Exercises Aimed at Treating Knee Osteoarthritis (iBEAT-OA)
Sameer Gohir¹, Abhishek Abhishek², Anthony Kelly² and Ana M Valdes³, ¹NIHR Nottingham Biomedical Research Centre, GRAYS ESSEX, England, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, England, United Kingdom
Background/Purpose: Osteoarthritis (OA) is the commonest cause of pain and disability in the general population and is usually managed by family doctors and physiotherapists. This…
Abstract Number: 1484 • ACR Convergence 2020
Efficacy of Tocilizumab in Patients with Hand Osteoarthritis: Double Blind, Randomized, Placebo Controlled, Multicenter Trial
Pascal Richette¹, Augustin Latourte², Jeremie Sellam³, Daniel Wendling⁴, Muriel Piperno⁵, Philippe Goupille⁶, Yves-Marie Pers⁷, Florent Eymard⁸, Sebastien Ottaviani⁹, Paul Ornetti¹⁰, Rene-Marc Flipo¹¹, Bruno Fautrel¹², Jean-Pierre Bertola¹³, Eric Vicaut¹⁴ and Xavier Chevalier¹⁵, ¹Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, ²Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, France, ³AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ⁴CHU Besançon, department of rheumatology, Besancon, France, ⁵Rheumatology Department, Lyon University Hospital, Lyon, France, ⁶CHU Tours, department of rheumatology, Tours, France, ⁷IRMB, University of Montpellier, Inserm U1183, University Hospital of Montpellier, Montpellier, France, ⁸APHP Henri Mondor Hospital, Creteil, France, ⁹Rheumatology Department, Bichat hospital, APHP, Paris, France, ¹⁰CHU Dijon, INSERM CAPS 1093, plateforme d’investigation technologique CIC1432, Dijon, France, ¹¹Lille University Hospital, Lille, France, ¹²Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹³CHUGAI PHARMA FRANCE, Paris, France, ¹⁴Clinical Research Unit, Paris, ¹⁵AP-HP, UPEC, Créteil
Background/Purpose: To evaluate the efficacy of tocilizumab, an antibody against interleukin-6 receptor (IL-6R), in patients with hand osteoarthritis.Methods: This was a multicenter, 12-week, randomized, double-blind,…
Abstract Number: 1485 • ACR Convergence 2020
LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis
Celeste Scotti¹, Joseph Gimbel², Didier Laurent¹, Aviv Madar³, Thomas Peters¹, Yunyu Zhang³, Florine Polus¹, Michael Beste³, Igor Vostiar¹, Subhajit Choudhury⁴, Nicole Gerwin¹, Jörg Goldhahn⁵, Matthias Schieker¹ and Ronenn Roubenoff¹, ¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Arizona Research Center, Phoenix, ³Novartis Institutes for BioMedical Research, Cambridge, ⁴Biostatistics & Pharmacometrics, Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁵Department of Health Sciences and Technology, ETH Zürich, Zurich, Switzerland
Background/Purpose:LNA043 is a modified human angiopoietin-like 3 (ANGPTL3) protein identified in a phenotypic screen for inducers of chondrogenesis and cartilage repair. The primary objective of…
Abstract Number: 1486 • ACR Convergence 2020
Long-term Efficacy and Safety of Intra-articular Sprifermin in Patients with Knee Osteoarthritis: Results from the 5-Year Forward Study
Felix Eckstein¹, Marc Hochberg², Hans Guehring³, Flavie Moreau⁴, Victor Ona⁴, Asger Bihlet⁵, Inger Byrjalsen⁵, Jeppe Andersen⁵, Benjamin Daelken³, Oliver Guenther³, Christoph Ladel³, Martin Michaelis³ and Philip G Conaghan⁶, ¹Paracelsus Medical University, Salzburg, Austria, ²University of Maryland School of Medicine, Baltimore, MD, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵Nordic Bioscience, Herlev, Denmark, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: The 5-year Phase II FORWARD study assessed the efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin (recombinant human fibroblast growth factor…
Abstract Number: 1487 • ACR Convergence 2020
Biclustering Reveals Potential Knee Osteoarthritis Phenotypes in Exploratory Analyses: Data from the Osteoarthritis Initiative
Amanda Nelson¹, Thomas Keefe², Todd Schwartz³, Richard Loeser¹, Yvonne Golightly⁴, Liubov Arbeeva¹ and J Marron², ¹University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina at Chapel Hill Dept of Biostatistics, Chapel Hill, NC, ⁴University of North Carolina at Chapel Hill Dept of Epidemiology, Chapel Hill, NC
Background/Purpose: To utilize novel methodologies to explore subgroups within the OAI clinical data.Methods: From the OAI baseline dataset (n=4796 individuals with or at risk of…
Abstract Number: 1488 • ACR Convergence 2020
Application of the Knee Injury and Osteoarthritis Outcome Score Percentile Curves on Preoperative and up to 2 Years Postoperative Data of Patients Undergoing Total Knee Arthroplasty
Marieke Loef¹, Maaike G. Gademan¹, Daisy A. J. Latijnhouwers¹, Herman Kroon¹, Herman Kaptijn², Willem Marijnissen³, Rob G. H. Nelissen¹, Thea Vliet Vlieland⁴ and Margreet Kloppenburg¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LangeLand Hospital, Zoetermeer, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Leiden University Medical Center, 2300 RC Leiden, Netherlands
Background/Purpose: The interpretation of patient-reported outcomes, such as the Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire, can prove difficult if benchmarks are lacking. Therefore,…
Abstract Number: 1489 • ACR Convergence 2020
Relation of Pain Mechanisms to Development of Knee Pain in Osteoarthritis: The Multicenter Osteoarthritis Study
Tuhina Neogi¹, Na Wang¹, Kosaku Aoyagi¹, Laura Frey Law², Cora Lewis³, Michael Nevitt⁴ and Lisa Carlesso⁵, ¹Boston University School of Medicine, Boston, MA, ²University of Iowa, Iowa City, IA, ³University of Alabama Birmingham, Birmingham, AL, ⁴University of California, San Francisco, San Francisco, CA, ⁵McMaster University, Hamilton, ON, Canada
Background/Purpose: Whether altered nociceptive signaling, such as pain sensitization and abnormal descending pain modulation, impact the risk of developing knee pain, more pain severity, and/or…
Abstract Number: 1490 • ACR Convergence 2020
Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials
Camila Pinto¹, Joana Barroso² and Thomas Schnitzer³, ¹Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Despite the known high inter- and intra-patient variability in analgesic responses in chronic pain, most interventional pain studies rely on single time point pain…
Abstract Number: 1491 • ACR Convergence 2020
Association of a Leaky Gut but Not Microbial Dysbiosis with Obesity-related OA: A Translational Study
Richard Loeser¹, Liubov Arbeeva¹, Kathryn Kelley², Anthony Fodor³, Shan Sun³, Veronica Ulici⁴, Lara Longobardi², Yang Cui², Susan Sumner², Andrea Azcarate-Peril², Balfour Sartor², Ian Carrol² and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³University of North Carolina-Charlotte, Charlotte, NC, ⁴Brown University, Providence, RI
Background/Purpose: To test the hypothesis that an altered gut microbiota (dysbiosis) plays a causal role in the obese OA phenotype (obesity with both hand and…
Abstract Number: 1492 • ACR Convergence 2020
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes
Yukiko Kimura¹, George Tomlinson², Laura Schanberg³, Mary Ellen Riordan⁴, Anne Dennos⁵, Vincent Del Gaizo⁶, Katherine Murphy⁷, Pamela F. Weiss⁸, Brian Feldman⁹ and Sarah Ringold¹⁰, ¹Hackensack Meridian School of Medicine, Hackensack, NJ, ²Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, ³Duke University Medical Center, Durham, NC, ⁴Hackensack University Medical Center, Westwood, NJ, ⁵Duke University, Durham, NC, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁷Lousiana Department of Public Health, New Orleans, LA, ⁸Children's Hospital of Philadelphia, Philadelphia, ⁹The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Seattle Children's, Seattle, WA
Background/Purpose: There is uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed…
Abstract Number: 1493 • ACR Convergence 2020
Distinct Patient-level Patterns of Response to Methotrexate in Juvenile Idiopathic Arthritis
Stephanie Shoop-Worrall¹, Kimme Hyrich², Lucy Wedderburn³, Wendy Thomson⁴ and Nophar Geifman⁵, ¹Centre for Health Informatics, Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, ²Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³UCL, UCLH, GOS Institute of Child Health, London, United Kingdom, ⁴Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Centre for Health Informatics, The University of Manchester, Manchester
Background/Purpose: Treatment response in JIA is often viewed as a binary outcome: response or non-response, usually assessed using composite, multidimensional measures, such as the juvenile…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].